Gait clinical trials

Explore recruiting gait clinical trials.

Recruiting gait studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Gait trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

StroKE34 Study Protocol: a randomized Controlled Phase IIa trial of intra-arterial Cd34+ Cells in acute ischemic Stroke

Portugal

Therapeutic exploratory (Phase II) EU CTIS Study details

Double-blind randomized acetazolamide trial in normal pressure hydrocephalus (DRAIN)

Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

Comparative study of the mechanism of action of Dry Needling and Botulinum Toxin type A as a treatment for lower limb post-stroke spasticity: a proof of concept controlled trial

Spain, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

Pharmacologically modulating the noradrenergic arousal system to reduce freezing of gait in Parkinson’s disease: a multi-center and multi-modal approach.

Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

Repurposing Everolimus to enhance musculoskeletal Vitality and Ageing in The Elderly (RENOVATE)

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

C3651003 A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENTS WITH CANCER, CACHEXIA, AND ELEVATED CONCENTRATIONS OF GDF-15, FOLLOWED BY AN OPTIONAL OPEN-LABEL TREATMENT PERIOD (PROACC -1)

Bulgaria, Poland, Spain, Slovakia

Therapeutic exploratory (Phase II) EU CTIS Study details

Gait trials by city

Gait in Toronto Gait in Vancouver Gait in Montreal Gait in Calgary Gait in Edmonton Gait in Ottawa Gait in Winnipeg Gait in Quebec City Gait in Hamilton Gait in Kitchener Gait in London Gait in Halifax Gait in New York Gait in Los Angeles Gait in Chicago Gait in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease